Uraemic encephalopathy (UE) is an acquired toxic syndrome characterised by delirium in patients with untreated or inadequately treated end-stage renal disease. UE is often associated with lethargy and confusion in the acute phase, which can progress to seizures, coma, or both in the chronic phase. Several neurobiochemical alterations have been reported in the acute and chronic phases of UE, including alterations in water transport and cerebral oedema, alterations in the blood–brain barrier, and changes in cerebral metabolism.
There are very few studies dealing with the epidemiology of the encephalopathic aspect of renal dysfunction. One study investigated cognitive impairment in patients on haemodialysis and found that among 374 patients on haemodialysis, 55 years or older, only 12.7% were completely cognitively intact. Almost 14% demonstrated mild cognitive impairment, 36.1% demonstrated moderate cognitive impairment, and 37.3% demonstrated severe cognitive impairment 1. Uraemic retention solutes, anaemia and hyperparathyroidism may play distinct roles in the pathogenesis of uraemic encephalopathy 2.
Uraemic encephalopathy presents as a complex syndrome which varies in its presentation from mild sensory clouding to delirium and coma, occasionally associated with myoclonus, asterixis, and seizures 3.
Animal studies have demonstrated impressive activations of biogenic amine expressing cell groups, stress-sensitive areas, and cell groups involved in the regulation of water and electrolyte homoeostasis, as well as central autonomic cell groups, in surgically and medically induced renal failure in rats 3. Data reported indicated that the acute uraemic state is an important factor that influences a variety of neurochemicals such as the biogenic amines (noradrenaline, adrenaline, histamine, and 5-hydroxytryptamine), as well as various brain areas such as stress-sensitive forebrain areas, neuronal cell groups involved in the regulation of water and electrolyte homeostasis, and central autonomic cell groups 3. Recent animal studies comparing acute uraemic encephalopathy with hepatic encephalopathy have demonstrated an increase in brain inflammation in conjunction with an increase in vascular permeability in uraemic encephalopathy 4. Local kidney injury may activate cytokines that cross the blood–brain barrier or activate other messengers that contribute to neuronal dysfunction. Alternatively, the retention of uraemic solutes may trigger both the inflammatory reaction and neuronal dysfunction 2.
Case reports and studies in humans have reported a number of biochemical changes in acute and chronic uraemic encephalopathy, including alterations in water transport and brain oedema, disturbances of the blood–brain barrier, and changes in cerebral metabolism 5-6. Anaemia, hyperparathyroidism and brain calcium concentrations have also been implicated in uraemic encephalopathy 7-8.
Macroscopic and microscopic features
Non-specific neuropathologic abnormalities have been described, including cerebral atrophy, gliosis, and foci of perivascular necrosis with accumulation of macrophages. Alzheimer type II astrocytes are often prominent. Patients may also develop changes of hypertensive encephalopathy 9.
UE is a syndrome in which the subcortical gray and white matter, midbrain and mesial temporal lobes become oedematous due to their exquisite sensitivity to metabolic alterations which is an inherent vulnerability related to the arterial perforators which supply these areas. The imaging features are thus consistent with cytotoxic oedema, localised in those areas.
Uraemic encephalopathy on CT typically presents as confluent bilateral hypodensity involving the basal ganglia, thalamus, and midbrain. The anatomical boundaries between the deep subcortical gray matter typically appear obliterated 10.
On MRI, UE typically presents as bilateral T2/FLAIR hyperintensities involving the basal ganglia, thalamus, midbrain and mesial temporal lobes. Restricted diffusion may or may not be present to a varying degree, but is not characteristic of uraemic encephalopathy. Enhancement is not a typical feature.
- Lentiform fork sign: is a characteristic feature of uraemic encephalopathy, in which the white matter surrounding the the basal ganglia - the internal and external capsules and the medullary laminae - become hyperintense on T2/FLAIR
Treatment and prognosis
Dialysis is the primary treatment for uraemic encephalopathy. This may be preceded by a period of peritoneal dialysis, which can be administered to ambulatory patients. Many patients ultimately require transplantation. Epileptic seizures, including nonconvulsive seizures, occur in up to one-third of all uraemic patients. In evaluating patients with seizures, it is essential to determine whether the seizure is the result of uraemia or the consequence of some other coexisting or causative illness such as malignant hypertension with encephalopathy, intercurrent infection, dialysis disequilibrium syndrome, or cerebral infarction. Usually the seizures caused by uncomplicated uraemia are generalized, but focal motor seizures and epilepsia partialis continua occur 11.
Other toxic encephalopathies such as acute liver failure and hepatic encephalopathy, metabolic disturbances such as disorders of glucose metabolism and disorders of water and electrolyte metabolism, and finally drug overdose and toxic exposures should also be considered.
The vast majority of toxic and metabolic disorders of the brain involve the deep gray nuclei (basal ganglia and thalamus) or the cerebral white matter. Typically, there is symmetric abnormality of the involved structures, which can provide a clue to the correct diagnosis 12.
- 1. Murray AM, Tupper DE, Knopman DS et-al. Cognitive impairment in hemodialysis patients is common. Neurology. 2006;67 (2): 216-23. doi:10.1212/01.wnl.0000225182.15532.40 - Pubmed citation
- 2. FRCP MWTMMMDF, Chertow GM, Marsden PA et-al. Brenner and Rector's The Kidney. Saunders. ISBN:1416061932. Read it at Google Books - Find it at Amazon
- 3. Chertow GM, Marsden PA et-al. Brenner and Rector's The Kidney. Saunders. ISBN:1416061932. Read it at Google Books - Find it at Amazon
- 4. Liu M, Liang Y, Chigurupati S et-al. Acute kidney injury leads to inflammation and functional changes in the brain. J. Am. Soc. Nephrol. 2008;19 (7): 1360-70. doi:10.1681/ASN.2007080901 - Free text at pubmed - Pubmed citation
- 5. Arieff AI, Massry SG, Barrientos A et-al. Brain water and electrolyte metabolism in uremia: effects of slow and rapid hemodialysis. Kidney Int. 1974;4 (3): 177-87. Pubmed citation
- 6. Mahoney CA, Sarnacki P, Arieff AI. Uremic encephalopathy: role of brain energy metabolism. Am. J. Physiol. 1984;247 (3 Pt 2): F527-32. Pubmed citation
- 7. Zamboni V, Cesari M, Zuccalà G et-al. Anemia and cognitive performance in hospitalized older patients: results from the GIFA study. Int J Geriatr Psychiatry. 2006;21 (6): 529-34. doi:10.1002/gps.1520 - Pubmed citation
- 8. Cogan MG, Covey CM, Arieff AI et-al. Central nervous system manifestations of hyperparathyroidism. Am. J. Med. 1979;65 (6): 963-70. Pubmed citation
- 9. Neuropathology: Expert Consult. Mosby. ISBN:0723435154. Read it at Google Books - Find it at Amazon
- 10. Kumar G, Goyal MK. Lentiform Fork sign: a unique MRI picture. Is metabolic acidosis responsible?. Clin Neurol Neurosurg. 2010;112 (9): 805-12. doi:10.1016/j.clineuro.2010.06.006 - Pubmed citation
- 11. Daroff RB, Fenichel GM, Jankovic J et-al. Bradley's Neurology in Clinical Practice: Expert Consult - Online and Print, 6e. Saunders. ISBN:1437704344. Read it at Google Books - Find it at Amazon
- 12. Osborn AG, Salzman KL, Barkovich AJ. Diagnostic Imaging. Lippincott Williams & Wilkins. (2009) ISBN:1931884722. Read it at Google Books - Find it at Amazon
Toxic and metabolic encephalopathies
- overview by region
- white matter
- grey matter
- by agent/substance
- by systemic illness
- overview by region
- by substance
- Wernicke encephalopathy (vitamin B1)
- by substance
- Kearns-Sayre syndrome
- Leigh syndrome
- mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)
- myoclonus epilepsy with ragged red fibres (MERRF)
- mitochondrial deletion syndromes
- progressive cerebral poliodystrophy (also known as Alpers syndrome)
- trichopoliodystrophy (also known as Menkes disease)